These findings suggest that genetic screening for TALDO1 variations, especially in populations at risk, may be relevant for preventing APAP‐induced liver injury and long‐term complications such as cirrhosis and HCC. This evidence concerns the gene TALDO1 and hepatocellular carcinoma.